Veterinary Medicines

Veloxa Forte Chewable Tablets for Dogs

Authorised
  • Febantel
  • Pyrantel
  • Praziquantel
Download as PDF

Product identification

Medicine name:
Veloxa Forte Chewable Tablets for Dogs
VELOXA XL COMPRIMES A CROQUER POUR CHIENS
Active substance:
  • Febantel
  • Pyrantel
  • Praziquantel
Target species:
  • Dog
Route of administration:
  • Oral use

Product details

Active substance and strength:
  • Febantel
    525.00
    milligram(s)
    /
    1.00
    Tablet
  • Pyrantel
    175.00
    milligram(s)
    /
    1.00
    Tablet
  • Praziquantel
    175.00
    milligram(s)
    /
    1.00
    Tablet
Pharmaceutical form:
  • Chewable tablet
Withdrawal period by route of administration:
  • Oral use
    • Dog
Anatomical therapeutic chemical veterinary (ATCvet) codes:
  • QP52AA51
Legal status of supply:
  • Veterinary medicinal product subject to veterinary prescription
Authorisation status:
  • Valid
Authorised in:
  • France
Package description:
  • PVC/Aluminium/Polyamide blister-forming laminate with aluminium lidding foil containing 2 chewable tablets. Box containing 1 blister strip of 2 chewable tablets (2 chewable tablets)
  • PVC/Aluminium/Polyamide blister-forming laminate with aluminium lidding foil containing 2 chewable tablets. Box containing 2 blister strips of 2 chewable tablets (4 chewable tablets)
  • PVC/Aluminium/Polyamide blister-forming laminate with aluminium lidding foil containing 2 chewable tablets. Box containing 4 blister strips of 2 chewable tablets (8 chewable tablets)
  • PVC/Aluminium/Polyamide blister-forming laminate with aluminium lidding foil containing 2 chewable tablets. Box containing 24 blister strips of 2 chewable tablets (48 chewable tablets)
  • PVC/Aluminium/Polyamide blister-forming laminate with aluminium lidding foil containing 2 chewable tablets. Box containing 48 blister strips of 2 chewable tablets (96 chewable tablets)

Additional information

Entitlement type:
  • Marketing Authorisation
Legal basis of product authorisation:
  • Generic application (Article 13(1) of Directive No 2001/82/EC)
Marketing authorisation holder:
  • Lavet Kft.
Marketing authorisation date:
Manufacturing sites for batch release:
  • Lavet Pharmaceuticals Ltd.
Responsible authority:
  • National Veterinary Medicines Agency
Authorisation number:
  • FR/V/0751813 7/2012
Date of authorisation status change:
Reference member state:
  • Hungary
Procedure number:
  • HU/V/0116/002
Concerned member states:
  • Austria
  • Belgium
  • Finland
  • France
  • Germany
  • Greece
  • Ireland
  • Italy
  • Luxembourg
  • Netherlands
  • Norway
  • Portugal
  • Spain
  • Sweden
  • United Kingdom (Northern Ireland)

Documents

Summary of Product Characteristics

This document does not exist in this language (English). You can find it in another language below.
French (PDF)
Published on: 7/04/2022
Download
How useful was this page?:
No votes yet
"Please do not include any personal data, such as your name or contact details. If you do, you consent to the processing of that data in accordance with EMA’s Privacy Statement concerning requests for information or access to documents. If you would like a reply from EMA, please Send a question to EMA instead."